Nebraska's highest court upheld the denial of workers' compensation death benefits to a widow who claimed her husband's ...

AstraZeneca and Daiichi Sankyo get FDA approval for Datroway's expanded use in triple-negative breast cancer treatment.

This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing ...

Junshi Biosciences receives approval of toripalimab NDA from NMPA for first-line treatment of HER2 expressing urothelial carcinoma: Shanghai Saturday, May 23, 2026, 17:00 Hrs [IST ...

Astellas Pharma India has announced that the Central Drugs Standard Control Organisation (CDSCO) has approved PADCEV ...

The Parker Institute for Cancer Immunotherapy (PICI) today announced that research and expertise from across its network will ...

Cambridge-headquartered Bicycle Therapeutics is accelerating a timely battle against bladder cancer. The company, based at ...

The regulator approved the toripalimab and disitamab vedotin combo for HER2-expressing urothelial carcinoma patients who had no prior systemic therapy.

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

VMPLMumbai (Maharashtra) [India], May 21: Astellas Pharma India today announced that PADCEV™ (enfortumab vedotin) in combination with pembrolizumab is now approved for the first-line treatment of ...

As of the April 20, 2026, data cut-off, 82 patients had been treated, and 72 had completed primary response evaluation. Dr.